Ding Xiaodi, Sheng Zhimei, Cui Jiayu, Cui Meimei, Zhang Liying, Feng Ruijun, Wang Yongming, Sun Wei, Zhang Xiurong, Shi Lihong, Zhang Baogang
Department of Pathology, Shandong Second Medical University, Weifang 261053, China.
Affiliated Hospital of Shandong Second Medical University, Weifang 261041, China.
Acta Biochim Biophys Sin (Shanghai). 2025 Mar 27;57(7):1047-1056. doi: 10.3724/abbs.2025017.
Studies of cell-to-cell activities in the tumor microenvironment (TME) have identified multiple potential targets for oncotherapy. The interplay between tumor cells and neighboring cancer-associated fibroblasts (CAFs) persists in all stages of tumor progression. In this study, we reveal that exosomes from breast cancer cells can be endocytosed into fibroblasts and transform normal fibroblasts (NFs) into CAFs and that the ability of exosomes from highly metastatic breast cancer cells is greater than that of those from poorly metastatic breast cancer cells. Further investigation reveals that exosomes from highly metastatic breast cancer cells contain much more miR-105-5p than those from poorly metastatic breast cells do and that exosomal miR-105-5p facilitates the transformation of NFs to CAFs. A detailed study reveals that RBMY1A1-dependent sorting of miR-105-5p into fibroblasts and subsequent internalization of miR-105-5p promote the transformation of NFs to CAFs by downregulating LATS2 expression and activating NF-κB signaling, which concurrently facilitates the EMT of breast cancer cells. Thus, our results indicate that exosomal miR-105-5p may be a potential target for novel therapeutic strategies to prevent the coevolution of breast cancer cells and CAFs.
对肿瘤微环境(TME)中细胞间活性的研究已经确定了多种肿瘤治疗的潜在靶点。肿瘤细胞与邻近的癌症相关成纤维细胞(CAFs)之间的相互作用在肿瘤进展的各个阶段都持续存在。在本研究中,我们发现乳腺癌细胞来源的外泌体可以被成纤维细胞内吞,并将正常成纤维细胞(NFs)转化为CAFs,且高转移乳腺癌细胞来源的外泌体的这种能力强于低转移乳腺癌细胞来源的外泌体。进一步研究发现,高转移乳腺癌细胞来源的外泌体比低转移乳腺癌细胞来源的外泌体含有更多的miR-105-5p,且外泌体miR-105-5p促进NFs向CAFs的转化。详细研究表明,RBMY1A1依赖的miR-105-5p分选进入成纤维细胞以及随后miR-105-5p的内化通过下调LATS2表达和激活NF-κB信号促进NFs向CAFs的转化,这同时促进了乳腺癌细胞的上皮-间质转化(EMT)。因此,我们的结果表明,外泌体miR-105-5p可能是预防乳腺癌细胞和CAFs共同进化的新型治疗策略的潜在靶点。